NuCana PLC (NASDAQ:NCNA) saw an uptick in trading volume on Tuesday . 845,116 shares changed hands during trading, an increase of 1,373% from the previous session’s volume of 57,379 shares.The stock last traded at $7.55 and had previously closed at $7.32.
Several research firms have weighed in on NCNA. BidaskClub raised shares of NuCana from a “strong sell” rating to a “sell” rating in a research report on Wednesday, July 31st. HC Wainwright began coverage on shares of NuCana in a research report on Monday. They set a “buy” rating and a $20.00 target price on the stock. William Blair reissued an “outperform” rating on shares of NuCana in a research report on Thursday, May 16th. ValuEngine raised shares of NuCana from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, Zacks Investment Research downgraded shares of NuCana from a “buy” rating to a “hold” rating in a research report on Tuesday, August 13th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $22.33.
The firm’s fifty day moving average price is $9.06 and its 200 day moving average price is $12.46. The firm has a market capitalization of $235.89 million, a PE ratio of -12.81 and a beta of 3.27.
NuCana Company Profile (NASDAQ:NCNA)
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. It is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; Phase Ib clinical trials for the treatment of recurrent ovarian cancer; Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary cancer; and Phase III clinical trials for the treatment of pancreatic cancer.
Featured Story: CD Ladder
Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.